Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:DBVNASDAQ:GBIOOTCMKTS:HIPHNASDAQ:IMNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AGBIOGeneration Bio$0.40+7.8%$0.39$0.32▼$3.65$26.68M2.66332,308 shs356,283 shsHIPHAmerican Premium Mining$0.00$0.00▼$0.00$6.44M2.071.92 million shsN/AIMNNImunon$1.14-20.3%$1.08$0.37▼$3.65$20.00M2.153.61 million shs3.52 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%GBIOGeneration Bio+7.83%0.00%+4.38%-28.94%-85.47%HIPHAmerican Premium Mining0.00%0.00%0.00%0.00%0.00%IMNNImunon-20.28%-14.29%+135.59%+31.02%+1.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AGBIOGeneration Bio4.0827 of 5 stars3.55.00.00.03.63.31.3HIPHAmerican Premium MiningN/AN/AN/AN/AN/AN/AN/AN/AIMNNImunon2.3137 of 5 stars3.42.00.00.03.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AGBIOGeneration Bio 3.00Buy$7.331,742.55% UpsideHIPHAmerican Premium Mining 0.00N/AN/AN/AIMNNImunon 2.75Moderate Buy$15.501,259.65% UpsideCurrent Analyst Ratings BreakdownLatest HIPH, DBV, IMNN, and GBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025IMNNImunonD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/13/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $17.005/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/7/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/26/2025IMNNImunonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/24/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.003/17/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AGBIOGeneration Bio$24.56M1.09N/AN/A$3.07 per share0.13HIPHAmerican Premium Mining$70K0.00N/AN/AN/ANaNIMNNImunon$500K40.00N/AN/A$1.42 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AGBIOGeneration Bio-$126.61M-$1.08N/AN/AN/A-782.86%-104.85%-49.54%8/6/2025 (Estimated)HIPHAmerican Premium MiningN/AN/A0.00N/AN/AN/AN/AN/AN/AIMNNImunon-$19.51M-$1.36N/AN/AN/AN/A-230.05%-128.98%8/13/2025 (Estimated)Latest HIPH, DBV, IMNN, and GBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025IMNNImunon-$0.35-$0.28+$0.07-$0.28N/AN/A5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million3/19/2025Q4 2024GBIOGeneration Bio-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AGBIOGeneration BioN/A6.346.34HIPHAmerican Premium MiningN/AN/AN/AIMNNImunonN/A2.302.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVInvesco DB G10 Currency Harvest Fund85.24%GBIOGeneration Bio95.22%HIPHAmerican Premium MiningN/AIMNNImunon4.47%Insider OwnershipCompanyInsider OwnershipDBVInvesco DB G10 Currency Harvest FundN/AGBIOGeneration Bio21.80%HIPHAmerican Premium MiningN/AIMNNImunon5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableGBIOGeneration Bio15067.04 million52.70 millionOptionableHIPHAmerican Premium Mining164.40 billionN/ANot OptionableIMNNImunon3017.54 million13.78 millionNot OptionableHIPH, DBV, IMNN, and GBIO HeadlinesRecent News About These CompaniesImunon Appoints Kimberly Graper as Interim CFOJune 13, 2025 | tipranks.comWall Street Zen Upgrades Imunon (NASDAQ:IMNN) to SellJune 8, 2025 | americanbankingnews.comTop Companies in the NASDAQ by Kalkine Leading Market Performers TodayJune 7, 2025 | kalkinemedia.comResearch Analysts Issue Forecasts for Imunon Q2 EarningsJune 7, 2025 | americanbankingnews.comIMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12thJune 6, 2025 | finance.yahoo.comASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancerJune 4, 2025 | finance.yahoo.comIMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 StudyJune 3, 2025 | globenewswire.comIMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers…June 2, 2025 | finance.yahoo.comIMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALSJune 2, 2025 | globenewswire.comImunon Inc. Faces Nasdaq Delisting Over Compliance IssuesJune 1, 2025 | uk.investing.comWhy Imunon, Inc. (IMNN) Surged Last WeekMay 31, 2025 | msn.comWhy Imunon, Inc. (IMNN) Surged Last WeekMay 31, 2025 | insidermonkey.comIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 29, 2025 | seekingalpha.comImunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M MoreMay 29, 2025 | insidermonkey.comIMUNON’s Stacy Lindborg on the long road to Phase IIIMay 28, 2025 | thepharmaletter.comIMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 28, 2025 | finance.yahoo.comImunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News SoonMay 28, 2025 | msn.comImunon announces up to $9.75M private placement priced at-the-marketMay 27, 2025 | finance.yahoo.comIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 27, 2025 | globenewswire.comIMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced ...May 25, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHIPH, DBV, IMNN, and GBIO Company DescriptionsInvesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.Generation Bio NASDAQ:GBIO$0.40 +0.03 (+7.83%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.40 +0.00 (+0.25%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.American Premium Mining OTCMKTS:HIPHAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.Imunon NASDAQ:IMNN$1.14 -0.29 (-20.28%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$1.15 +0.01 (+0.88%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
